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Abstract Central apnea during sleep represents a mani-
festation of breathing instability in many clinical
conditions of varied etiologies. Central apnea is the result
of transient cessation of ventilatory motor output, which
represents that inhibitory inﬂuences favoring instability
predominate over excitatory inﬂuence favoring stable
breathing. This article will review the determinants of
central apnea, the speciﬁc features of CHF-related central
apnea, and outline a management approach
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Determinants of central apnea during NREM sleep
The removal of the wakefulness ‘‘drive to breathe’’ renders
respiration during sleep (speciﬁcally non-rapid eye move-
ment or NREM sleep) critically dependent on chemical
inﬂuences, especially PCO2. NREM sleep unmasks a
highly sensitive, hypocapnic apneic threshold; accordingly,
central apnea occurs if arterial PCO2 is lowered below the
‘‘apneic threshold’’ [1, 2]. This can be induced experi-
mentally via passive nasal mechanical ventilation resulting
in hypocapnia of varied degrees.
Hypocapnia is the most ubiquitous and potent inﬂuence
favoring inhibition of ventilatory motor output in sleeping
humans. However, some types of hyperventilation,
including brief and active hyperventilation, may not result
in apnea. Hypoxic hyperventilation, and possibly other
forms of active hyperventilation, may be associated with
activation of an excitatory neural mechanism referred to as
short-term potentiation (STP) [3–5]. This neuronal phe-
nomenon may preserve rhythmic respiration despite
transient hypocapnia. In fact, termination of brief hypoxia
or transient arousals from sleep rarely lead to central apnea
despite hypocapnia at or below the apneic threshold [5, 6].
However, prolonged hypoxia may abolish STP, which may
explain the development of periodic breathing after 20–
25 min of hypoxia and the occurrence of central apnea
upon termination of prolonged hypoxic exposure [5, 7].
Likewise, central apnea does not usually occur following
brief episodes of hyperventilation in sleeping humans [8]
or dogs [9] possibly due to insufﬁcient reduction in PCO2
at the level of the central chemoreceptors.
Central apnea can also occur through non-chemical
pathways; for example, application of negative pressure
and subsequent deformation of the upper airway lead to
central apnea in a canine model [10]. Likewise, central
apnea is more frequent in the supine position [11–13] and
may respond to nasal continuous positive airway pressure
therapy (CPAP) [14]. In fact, the lateral position may lead
to amelioration of severity of central apnea and Cheyne–
Stokes respiration [11–13].
Apnea does not occur as an isolated event but in clusters
of breaths separated by intervals of apnea or hypopnea.
This has given rise to the maxim: apnea begets apnea.
Patients with CHF and central apnea often display the
typical crescendo-decrescendo pattern of Cheyne–Stokes
respiration. This form of periodic breathing represents a
cumulative effect of physiologic ventilatory responses
aiming to minimize the ﬂuctuation in arterial blood gases.
Changes in PCO2 and PO2 produce proportional counter-
acting changes in ventilation; however, a delayed or
exaggerated response produces periodic rather than stable
breathing.
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underpin the notion that physiologic responses lead to
pathologic instability. The ventilatory control system
operates as a negative-feedback closed-loop cycle to
maintain homeostasis of blood gas tensions within a
physiologic range. Many authors have adopted the engi-
neering concept of ‘‘loop gain’’ (GL) as a measure of
ventilatory stability or susceptibility to central apnea and
recurrent periodic breathing [15]. Loop gain represents the
overall response of the plant (representing the lung and
respiratory muscles), the controller (representing the ven-
tilatory control centers and the chemoreceptors), and the
delay, dilution, and diffusion inherent in transferring the
signal between the plant and the controller. There are
several excellent reviews discussing the dynamics of ven-
tilatory control in humans [16–18].
The occurrence of apnea leads to several consequences
that conspire to promote further breathing instability. The
ﬁrst is the inertia of the ventilatory control system that
prevents the return of rhythmic breathing until PaCO2
increases by 4–6 mmHg above eupneic arterial PCO2 [19].
In addition, central apnea is associated with narrowing or
occlusion of the pharyngeal airway [20]. Thus, resumption
of ventilation requires opening of a narrowed or occluded
airway and overcoming tissue adhesion forces [21] and
cranio-facial gravitational forces. Termination of central
apnea is associated with variable asphyxia (hypoxia and
hypercapnia) and transient arousal, resulting in ventilatory
overshoot, subsequent hypocapnia, and further apnea/
hypopnea. This sequence explains the overlap between
central and obstructive apnea (upper airway obstruction
often follows central apneas upon resumption of respiratory
effort, i.e., mixed apnea).
Pathophysiologic classiﬁcation of central sleep apnea
The classiﬁcation of central apnea as hypercapnic or non-
hypercapnic (based on the level of daytime PaCO2) does
not capture the continuum of ventilatory abnormalities in
clinical conditions. Physiologically, central apnea could be
caused by reduced alveolar ventilation or by hypocapnia
following alveolar hyperventilation.
Central sleep apnea, in its hypercapnic form, is caused by
removal of the wakefulness stimulus to breathe in patients
with neuromuscular hypoventilation disease or severe
abnormalities in pulmonary mechanics [22]. Therefore, it is
a form of nocturnal ventilatory failure in patients with
marginal ventilatory status or worsening of existing chronic
ventilatory failure. Arousal from sleep restores alveolar
ventilation to a variable degree; resumption of sleep reduces
ventilation in a cyclical fashion. This type of central apnea
does not necessarily meet the strict criteria of ‘‘central’’ or
of ‘‘apnea’’. Consequently, the presenting clinical picture
includes both features of the underlying ventilatory insuf-
ﬁciency and features of the sleep apnea/hypopnea
syndrome. This type of central apnea is uncommon in
patients with CHF unless a concomitant neuromuscular
disease of chest wall deformity is present.
Hypocapnia secondary to hyperventilation is the most
common underlying mechanism of central apnea and the
most relevant mechanism in patients with CHF. This type
of apnea occurs in the absence of daytime alveolar
hypoventilation; in fact, common features include hyper-
ventilation and hence hypocapnia, even during wakefulness
[23] with no evidence of a neuromuscular disorder,
abnormal lung mechanics, or impaired responses to
chemical stimuli. Oscillating sleep state at sleep onset [24]
or transient hypoxia possibly due to reduced lung volumes
in obese supine patients may trigger the ‘‘ﬁrst’’ apnea and
set in motion the process of apnea-hyperapnea and leads to
sustained breathing instability, manifested as periodic
breathing (see above).
Central apnea risk factors
Several physiologic or pathologic factors inﬂuence the
susceptibility to central apnea including sleep state, age,
gender, sleep state, and several medical conditions.
Sleep state exerts a major inﬂuence on breathing during
sleep. Breathing instability is likely to occur at sleep onset
as sleep state oscillates [24–27], with reciprocal oscillation
in PaCO2 around the hypocapnic apneic threshold. Con-
sequently, central apnea may occur if sufﬁcient hypocapnia
occurred; recovery from apnea is associated with transient
wakefulness and hyperventilation. The subsequent hypo-
capnia elicits apnea upon resumption of sleep.
Consolidation of sleep stabilizes PaCO2 at a higher set
point above the apneic threshold. Interestingly, central
apnea may occur without preceding hyperventilation at the
transition from alpha to theta sleep in normal subjects and
is associated with prolongation of breath duration [28].
Post-hyperventilation central sleep apnea is uncommon
during REM sleep, suggesting that REM sleep is imper-
vious to chemical inﬂuences owing to increased ventilatory
motor output [29, 30].
Aging is associated with increased prevalence of central
sleep apnea [31–33]. Possible causes include age-related
sleep state oscillations [24, 34]; co-morbid conditions such
as thyroid disease [35], congestive heart failure [36], atrial
ﬁbrillation [37], and cerebrovascular disease [38], or that
aging per se may contribute to increased susceptibility to
develop central apnea in older adults [32].
Central sleep apnea is uncommon in pre-menopausal
women [39]. There is evidence that women are less
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relative to men following mechanical ventilation. Physio-
logically, the hypocapnic central apneic threshold is higher
in men relative to women [2]. Administration of testos-
terone to healthy pre-menopausal women elevates the
apneic threshold [40]. Conversely, suppression of testos-
terone with leuprolide acetate in healthy males decreases
the hypocapnic-apneic threshold and potentially stabilizing
respiration [41]. Thus, male sex hormones are the most
likely factor elevating the apneic threshold in men.
Sleep apnea is common after a cerebrovascular accident
(CVA) [38, 42, 43], with central apnea being the predomi-
nanttypein40%ofpatientsofsleepapneaafteraCVA[43].
Likewise, central apnea occurs in 30% of patients stable
methadone maintenance treatment [44]. Finally, several
medical conditions predispose to the development of central
apnea including hypothyroidism, acromegaly, and renal
failure [45–49], all of which have an unexpectedly high
prevalence of sleep apnea. Nocturnal hemodialysis is asso-
ciated with improvement in sleep apnea indices [48].
Some patients may manifest central apnea with no
apparent risk factor and are considered to have ‘‘idiopathic
central apnea’’, associated with increased chemo respon-
siveness and sleep state instability [50, 51]. Nevertheless, it
is possible that these patients will have occult cardiac or
metabolic disease. For example, idiopathic central sleep
apnea is more prevalent in patients with atrial ﬁbrillation.
Sleep apnea is highly prevalent in patients with CHF [36,
52–54]. Javeheri et al. demonstrated that 51% of male
patients with CHF had sleep-disordered breathing, 40% had
central sleepapnea,and 11%obstructiveapnea.Risk factors
for CSA in this group of patients include male gender, atrial
ﬁbrillation, age [60 years, and daytime hypocapnia
(PCO2\38 mmHg) [55]. Risk factors for OSA differed by
gender; the only independent determinant in men was body
mass index (BMI), whereas age over 60 was the only inde-
pendent determinant in women.
The presence of pulmonary vascular congestion in
patients with central apnea and CHF leads to hyperventi-
lation and hypocapnia [36]. Paradoxically, steady-state
hypocapnia is stabilizing by virtue of decreased plant gain
[56–58]. In other words, steady-state reduction of PaCO2 is
potentially stabilizing rather than destabilizing as is com-
monly thought. However, the apneic threshold in patients
with central apnea and CHF is precariously close to the
eupneic PCO2, because of increased chemoreﬂex sensitiv-
ity or controller gain.
Clinical features and diagnosis
Patients with central apnea may present with the usual
symptoms of sleep apnea syndrome, or with insomnia and
poor nocturnal sleep. These symptoms may be due to sleep
fragmentation secondary to recurrent apnea. In fact, poor
nocturnal sleep may be a presenting symptom in patients
with central apnea due to CHF. Diagnosis of central sleep
apnea requires nocturnal polysomnography and accurate
detection of ﬂow, measurement of oxyhemoglobin satura-
tion, and detection of respiratory effort [59].
Accurate detection of respiratory effort is important to
distinguish central from obstructive apnea. Cardiogenic
oscillations (pulse artifacts) on the ﬂow signal are often
used as evidence of central etiology and a patent upper
airway. The underlying rationale is the pulse artifacts
represent transmission of a pulse waveform from the tho-
rax, and hence indicates a patent upper airway that allows
the transmission of cardiogenic oscillation. However, there
is evidence that this index is invalid to ascertain upper
airway patency. Morrell et al. [60] used ﬁber optic naso-
pharyngoscopy to evaluate upper airway patency during
central apnea; cardiogenic oscillations were present even
when the airway is completely occluded.
Other measurement of effort include measurement of the
lapsed time for the pulse signal to reach the periphery, or
pulse transit time (PTT) [59]. The technique measures the
elapsed time between R wave on the ECG and the arrival of
the pulse wave to the ﬁnger. The underlying physiologic
principle is that blood pressure inﬂuences vessel stiffness
and hence the speed of the pulse wave. When blood pres-
sure increases during an obstructive apnea owing to
increased intra-thoracic pressure swings, the pulse transit
time displays parallel swings.
Management
Central apnea syndrome is a disorder with protean under-
lying conditions, therefore requiring a full panoply of
therapeutic options. Management strategy incorporates
underlying conditions, polysomnographic features, and
individual factors. Optimal treatment of the underlying
condition is a prerequisite component of the management
plan in every patient. This is particularly important in
patients with CHF where improvement of cardiac function
may ameliorate central apnea. Likewise, diuresis may
decrease pulmonary vascular congestion, improve oxy-
genation, and minimize overshoot. Speciﬁc therapeutic
options include positive pressure therapy, pharmacologic
therapy, and supplemental O2.
Positive pressure therapy
Central apnea may respond to nasal CPAP therapy, espe-
cially if it occurred in combination with episodes of
obstructive or mixed apnea. Moreover, pure central sleep
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reasons: (i) preventing pharyngeal narrowing during central
apnea [14], (ii) improved oxygenation by increased lung
volume, and (iii) improving cardiac function by decreasing
pre-load and after load. The aggregate of these changes
would dampen the ensuing ventilatory overshoot and per-
petuation of ventilatory instability [20]. In fact, nasal
CPAP is often effective in reversing central sleep apnea,
even in the absence of concomitant obstructive apnea [14],
possibly by preventing upper airway closure and sub-
sequent ventilatory overshoot [20]. This may also explain
the reported increase in PCO2 after CPAP [61]. Similarly,
nasal CPAP therapy in patients with central sleep apnea
and CHF produced increased left-ventricular ejection
fraction (LVEF) and a reduction of combined mortality-
cardiac transplantation risk by 81%, but only in patients
with CSA [62].
The exuberance regarding nasal CPAP therapy in
patients with central apnea and CHF did not withstand the
rigors of controlled clinical trials. The Canadian Continu-
ous Positive Airway Pressure trial, or CANPAP [63], tested
the hypothesis that CPAP would improve the survival rate
without heart transplantation in patients with heart failure
and central sleep apnea. The study enrolled 258 patients
who had heart failure and central sleep apnea; participants
were randomly assigned to the nasal CPAP treatment group
(n = 128) or no CPAP (130 patients). Duration of follow
up was for a mean of 2 years. There was greater
improvement in the CPAP group at 3 months relative to the
placebo group as evidenced by greater reductions in apnea-
hypopnea index, ejection fraction, mean nocturnal oxyhe-
moglobin saturation, plasma nor-epinephrine levels, and
the distance walked in 6 min at 3 months. Nevertheless,
there was no difference in the overall event rates (death and
heart transplantation) between the two groups. Thus, nasal
CPAP had no effect on survival, despite the effect on the
‘‘severity’’ of central apnea and several intermediate out-
come variables. Nevertheless, a post-hoc analysis has
shown decreased mortality if CPAP therapy resulted in
amelioration of central sleep apnea. Therefore, current
evidence does not support the use of CPAP to extend life in
patients who have heart failure and central sleep apnea
unless evidence of response is demonstrated by
polysomnography.
The major ﬁnding of CANPAP was the absence of a
survival beneﬁt for nasal CPAP therapy. Nasal CPAP
therapy had no effect on heart transplant-free survival;
however, aggregate data showed only a modest reduction
of AHI to 19 events per hour of sleep; a cutoff of 15 events/
h was the inclusion threshold for the study and remains a
commonly accepted threshold for pathologic AHI. Another
limitation of the study was that nasal CPAP therapy was
not titrated under polysomnographic monitoring but
increased gradually to 10 cm/H2O or to the highest toler-
ated number. Optimal CPAP pressure was not determined.
In addition, only 100 of the 128 randomized to CPAP
underwent repeat polysomnography after 3 months of nasal
CPAP therapy [64]. Fifty-seven patients responded to nasal
CPAP as evidenced by decreased AHI below 15/h of sleep.
Interestingly, the responders (CPAP-CSA-suppressed)
group demonstrated a statistically signiﬁcant increase in
LVEF at 3 months (P = 0.001) and a higher transplant-
free survival than control subjects. Conversely, the
non-responders (CPAP-CSA-unsuppressed) group demon-
strated no increase in either variable. These ﬁndings
suggest that improvement in LVEF may be a marker of
improved survival. In addition, this study highlights the
need to conform optimal response to patients with CHF-
CSA. Lowering AHI below 15 events/h of sleep may be
suboptimal in terms of improved nocturnal respiration,
cardiac function, or mortality.
Non-invasive positive pressure ventilation (NIPPV)
using pressure support mode (bi-level nasal positive pres-
sure) is a therapeutic option in patients with nocturnal
ventilatory failure and central apnea secondary to hypo-
ventilation. However, there is little evidence to support its
use in non-hypercapnic central apnea including CHF. In
fact, NIPPV in the pressure support, bi-level mode aug-
ments tidal volume, leading to hypocapnia and possible
worsening of central apnea and periodic breathing during
sleep [65]. Meza et al. [66] have shown that application of
pressure support ventilation results in periodic breathing in
most normal subjects when the pressure gradient is above
7 cm/H2O.
Recent technological advances allowed for variations in
the mode of delivering positive pressure ventilation. One
such method is adaptive servo ventilation (ASV) that
provides a small but varying amount of ventilatory support
against a background of low level of CPAP. Contrary to bi-
level, pressure support devices, changes in respiratory
effort result in reciprocal changes in the magnitude of
ventilatory support. Thus, ventilation remains slightly
below the baseline, eupneic average. There is evidence that
ASV is more effective than CPAP, bi-level pressure sup-
port ventilation, or increased dead space in alleviating
central sleep apnea [67].
Pharmacological therapy
Pharmacological therapy is of marginal role in central
apnea. Small studies suggest acetazolamide and theophyl-
line may be beneﬁcial in the treatment of central apnea
[68]. Acetazolamide is a carbonic anhydrase inhibitor and a
weak diuretic that causes mild metabolic acidosis. Aceta-
zolamide ameliorates central sleep apnea when
administered as a single dose of 250 mg before bedtime
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Cheyne–Stokes respiration in patients with CHF [70],
without adverse effect on sleep architecture. Pharmaco-
logic therapy remains an unfulﬁlled opportunity that awaits
further research.
Several pharmacologic agents may inﬂuence the pro-
pensity to develop central apnea; therefore, medication use
is an important consideration in the management patients
with central sleep apnea. For example, the use of beta-
blockers in patients with central sleeps apnea and conges-
tive heart failure is associated with reduced apnea index.
Conversely, narcotics may worsen central apnea; a change
in the pain control regimen may ameliorate the severity of
central apnea [44, 71].
Supplemental O2 and CO2
Supplemental O2 therapy may be beneﬁcial in patients with
idiopathic central sleep apnea and patients with CHF-CSR
[36, 72], most likely by ameliorating hypoxemia and
minimizing the subsequent ventilatory overshoot. In addi-
tion, supplemental O2 may alleviate central apnea by
increasing cerebral PCO2 through the Haldane effect.
Likewise, supplemental CO2 abolishes central apnea in
patients with pure central sleep apnea. The mechanism of
action is by raising PCO2 above the apneic threshold.
However, this therapy is not practical given the need for a
closed circuit to deliver supplemental CO2.
Approach in selected clinical syndromes
1. It is imperative to optimize treatment of the underlying
condition such as CHF.
2. Titration of CPAP in the sleep laboratory is beneﬁcial
to ascertain response to nasal positive airway pressure
therapy. This may determine whether long-term treat-
ment is of beneﬁt.
3. The optimal pressure settings have to be determined in
a titration polysomnogram.
4. The use of B-PAP in a pressure support mode may
aggravate the severity of central apnea. ASV is a
promising therapeutic modality for CHF-CSR.
5. Supplemental O2 may be beneﬁcial, particularly in
patients with CHF-CSR.
6. The use of pharmacologic agents remains uncommon.
Additional studies are needed.
Summary
The pathogenesis of central sleep apnea varies depending
on the clinical condition. Sleep-related withdrawal of the
ventilatory drive to breathe is the common denominator
among all cases of central apnea, whereas hypocapnia is
the ﬁnal common pathway leading to apnea in non-
hypercapnic central apnea. The pathophysiologic hetero-
geneity may explain the protean clinical manifestations and
the lack of a single effective therapy for all patients.
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